A local veteran fighting breast cancer received an unforgettable surprise from the NFL, the Super Bowl Planning Committee and ...

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

If you have metastatic breast cancer, you may need help from loved ones and your medical team along the way. Here’s how to ...

Several studies show that isolation is very common among those diagnosed with metastatic breast cancer. However, there are ...

The findings suggest that reconsideration of current clinical guidelines, which support MRI only for symptomatic brain ...

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung ...

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

Patients diagnosed with more advanced breast cancer are more likely to have cardiovascular disease, a large study suggests.